# Cannabis for Management of Chronic Spine Pain

#### Emily M. Lindley PhD

Assistant Professor
University of Colorado
Anschutz Medical Campus
Department of Orthopedics



#### Overview of Presentation

- Cannabis use in Colorado Spine Patients
- State-funded study
  - Background
  - Study Aims & Design
  - Status
  - Future Studies



## **Background**

- Patients were increasingly reporting use of cannabis to self-medicate for their spine pain
- 2012: Survey of 184 patients presenting to UCH Spine Clinic
  - 19% reported cannabis use for pain control
  - Users: 44 yo (18-84)
  - Non-users: 54 yo (18-87)
  - 68% had spine condition >1 year
- Method of <u>use</u>
  - Smoke plant material: 45%
  - Smoke + Edibles: 19%
  - Smoke + Vaporize: 10%
  - Smoke + Vaporize + Edibles: 10%







## **Background**

#### Pain Efficacy

85%: moderately/very much relieved pain

#### Cannabis vs Other Pain Medications

- 77%: better/equal to NSAIDS
- 77%: better/equal to opioids
- 86%: better/equal to nerve-targeted medications (Lyrica, Neurontin)



### **Background**

- Historically, most clinical trials of cannabinoid-based drugs have focused on cancer pain
- 8 RCTs studied smoked (4) or vaporized (4) cannabis vs placebo for neuropathic pain (diabetic/peripheral neuropathy, spinal cord injury/disease)
  - All showed significant improvement pain
  - No serious adverse events
- No evidence for cannabis use in chronic spine pain...

#### "Expert" Evidence on Cannabis



- RCT (double blind)
- 2 cohorts of subjects:
  - 50 Chronic Back/Neck Pain
  - 50 Healthy Controls
- Study drugs:
  - Cannabis (4-8 puffs of 5% THC; expected range 4.5-5.4%)
    - Flexible dosing scheme: Self-titrate to achieve desired balance of drug effect vs side effects
      - Twice as likely to observe significant differences between placebo and active drug
      - Reduce AE's from supratherapeutic dosing
  - Oxycodone hydrochloride, immediate release (5 or 10 mg)
  - Placebo cannabis (cannabinoids extracted via ethanol)
  - Placebo oxycodone



- Cannabis: National Institute on Drug Abuse (NIDA) source grown at U of Mississippi
  - 1970's
  - 2015: NIDA renewed \$68.8 million dollar contract
  - Indoor grow rooms & outdoor Cannabis Garden












- Vaporization
  - Allows active cannabinoid vapors to form
  - Does not heat to the point of combustion (i.e. release of toxins)
  - Little if any increase in exhaled carbon monoxide after vaporization
  - However, effects on pulmonary outcomes have not been studied



Subjects come in for 3 separate 4-hour study visits

Vaporized

**Cannabis** 

Placebo pill

Vaporized Placebo +

Oxycodone pill

Vaporized

**Placebo** 

+

Placebo pill







#### **Primary Study Aims**:

#### Effect of Study Drugs on:

- Relief of back and neck pain (spine patients)
- Sensitivity to experimentallyinduced pain (healthy controls)



#### **Secondary Study Aims**:

#### Effect of Study Drugs on:

- Patient's global impression of changes in their chronic spine pain condition
- Subjective reports of drug, psychoactive and mood effects (feeling high, impaired, confused, anxious, nauseated, good drug effect, bad drug effect, etc.)
- 3. Tests of neurocognitive functioning (attention, concentration, memory, fine motor control)
- 4. Standardized Field Sobriety Tests
- 5. AE's



# Regulatory Approvals & Status of Study

- University and Hospital Support
  - Study drug storage room with high level security: keyless code entry, security cameras inside & outside room, padlocked freezer with keyed drug boxes inside, double-locked narcotics cabinets
  - Study drug administration room renovated to included HVAC system
  - 18 months
- Local Regulatory Approvals
  - Scientific Advisory and Review Committee (SARC) approved scientific merit: 3 months
  - IRB (COMIRB): 1 month
- FDA approval of IND: 1 month
- DEA approval of Schedule I/II registrations
  - 6 months for approval, 8 months to get valid registrations
- NIDA approval for cannabis request



# Regulatory Approvals & Status of Study

27 months

**Grant Award** 

**|** 

Receipt of Cannabis Product

#### Status of Study

- Currently enrolling:
  - Phone Screens: 74
    - 64 fails: frequent cannabis use, other pain/medical conditions
    - 10 passes



- Screen Visits: 8
  - 7 fails: abnormal lab result, psychiatric condition, other pain condition
  - 1 pass



Study Visits: 1 scheduled

#### Future Studies/Considerations

- Extended use of study drugs
- Transition from opioids alone to opioids + cannabis, or cannabis alone
- Other cannabinoids
  - CBD
  - THC/CBD
- Other preparations
  - Extracts
  - Creams/Patches
  - Edibles??